Cargando…
Pharmacokinetic Study of NADPH Oxidase Inhibitor Ewha-18278, a Pyrazole Derivative
In a previous study, the specific NOX1/2/4 inhibitor Ewha-18278 was confirmed as a possible treatment for osteoporosis both in vitro and in vivo. Here, we investigated the pharmacokinetics (PK) of the compound by intravenous (IV) and oral administrations to rats. Dimethyl sulfoxide (DMSO)-based and...
Autores principales: | Lee, Seul Gee, Lee, Jaeok, Kim, Kyung Min, Lee, Kee-In, Bae, Yun Soo, Lee, Hwa Jeong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781499/ https://www.ncbi.nlm.nih.gov/pubmed/31533299 http://dx.doi.org/10.3390/pharmaceutics11090482 |
Ejemplares similares
-
A novel pyrazole derivative protects from ovariectomy-induced osteoporosis through the inhibition of NADPH oxidase
por: Joo, Jung Hee, et al.
Publicado: (2016) -
Function of NADPH Oxidases in Diabetic Nephropathy and Development of Nox Inhibitors
por: Lee, Sae Rom, et al.
Publicado: (2020) -
NADPH oxidase inhibitor development for diabetic nephropathy through water tank model
por: Lee, Hye Eun, et al.
Publicado: (2022) -
Cohort profile: the Ewha Birth and Growth Study
por: Lee, Hye Ah, et al.
Publicado: (2021) -
NADPH Oxidase 1 and NADPH Oxidase 4 Have Opposite Prognostic Effects for Patients with Hepatocellular Carcinoma after Hepatectomy
por: Ha, Sang Yun, et al.
Publicado: (2016)